Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
34.57
+1.66 (5.04%)
Aug 19, 2026, 4:00 PM EDT - Market closed

Quince Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-60.8-50.43-36.17-24.64-50.09-90.32
Net Income
-92.48-83.98-56.83-31.39-51.66-89.95
Earnings Per Share
-51.81-335.27-262.71-168.57-308.45-605.31
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
115.9817.7540.7875.0690.18106.8
Total Debt
-18.4714.8113.810.451.16
Net Cash (Debt)
115.98-0.7225.9761.2589.73105.64
Net Cash Growth
573.52%--57.59%-31.74%-15.06%-20.79%
Net Cash Per Share
64.97-2.87120.07328.95535.74710.94

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-46.92-41.43-31.9-18.29-44.04-62.93
Capital Expenditures
-0.08-0.35-0.26-0.16-0.13-0.18
Free Cash Flow
-47-41.78-32.16-18.45-44.17-63.11
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.